Botulinum toxin vs crosslinked HA filler
This page places verifiable specifications side by side. It does not rank materials, score them, or recommend one over another.
Comparison
What is the difference between botulinum toxin and hyaluronic acid filler?
These two share no mechanistic step at all beyond arriving through a syringe. One reduces the signal running from nerve to muscle at the neuromuscular junction; the other places matrix in the dermis. The distance is widest at the regulatory level: in the two markets where classification could be established, the first is a drug and the second is a medical device, which means who may supply them and what may be said about them in public are set by different bodies of law.
| Aspect | Botulinum toxin type A | Crosslinked HA (hyaluronic acid filler) | Basis |
|---|---|---|---|
| Family | Bacterial neurotoxin protein | Crosslinked polysaccharide hydrogel | — |
| Site of action | Neuromuscular junction | The dermal or subdermal plane it is placed in | — |
| Extracellular matrix involvement | None — the only entry in this reference that does not act on the extracellular matrix | Supplies matrix — hyaluronan is a native constituent of the dermal extracellular matrix | — |
| Regulatory identity — Korea | Medicinal product under the Pharmaceutical Affairs Act | Medical device — biomaterial for tissue restoration | Legal text |
| Regulatory identity — United States | Biologics licence BLA 103000, marketing status listed as prescription | Premarket approval PMA P020023, generic name 'implant, dermal, for aesthetic use' | Legal text |
| Means of degradation or removal | No corresponding agent is recorded in this reference | Reviews record that the gel is degradable with hyaluronidase | — |
| Whether dose notation carries across products | Potency units are measured by manufacturer-specific assays and do not convert between preparations | Stated as volume in mL; the properties used to distinguish products are rheological | — |
| Study placing both in one protocol | Glabellar frown, toxin alone compared with toxin plus hyaluronic acid filler (PMID 35552477, 40 subjects, level of evidence III) | Same study — the combination arm received the same toxin dose plus 0.45 mL of hyaluronic acid filler | Legal text |
They are grouped by route, not by mechanism
These two are almost always discussed in the same sentence. Look for what they share and you find one thing: they arrive through a syringe. At the level of mechanism there is no overlap anywhere. One reduces the signal from nerve to muscle, so the movement that folds the skin is reduced and nothing happens in the dermis at all. The other places material in the dermis and occupies that space. “Both are used for wrinkles” is a grouping made from the outcome end, not from the acting end.
The widest gap is the regulatory lane
In the two markets where this reference could establish a classification, the first is a drug and the second is a device. In Korea two different bodies of law apply — the Pharmaceutical Affairs Act on one side, the device regulations on the other. In the United States they travel different pathways: a biologics licence and a premarket approval.
That difference does not stop at paperwork. Prescription medicines are restricted from advertising to the general public, so the range of what may be said in a given setting differs between the two materials. It is why this page describes substance and pathway and stops there.
What the combination study actually observed
The cited study divided glabellar frown into two arms: toxin alone, and the same toxin dose plus 0.45 mL of hyaluronic acid filler. It reported that the difference in wrinkle scale scores between the arms reached statistical significance at weeks 20 and 28.
The question that design answers is not “which of the two” but “does adding one to the other change anything”. The result is consistent with the description that the two act on different components, but it should be read inside its conditions: one site, one protocol, 40 subjects, level of evidence III.
What is not on this page
There is no duration comparison. Placing the two on one duration axis would require a study observing the same outcome measure over the same period, and no such design was found in the searches behind this reference. The duration figures commonly quoted come from separate studies of each material, and setting numbers measured on different scales side by side is not a comparison.
Limitations & open questions
The combination study covers one site (glabella) under one protocol, and the authors assigned it level of evidence III. It enrolled 40 subjects and followed them to 28 weeks. It is not a design that can weigh the two materials against each other, and because they act on different targets, placing them on a single outcome measure does not hold in the first place — that study did not set them against each other but added one to the other. This reference carries no efficacy figures for either material, because reported outcomes depend on dose, site and injection technique, and all three vary across published protocols.